Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 3/20 | 0.50 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2949434 | 0.99 | GRM2 (0.49) | GRM2CYSLTR1MAPTL3MBTL1HTT | |
| SCHEMBL2940441 | 0.89 | MRGPRX4 (0.54) | GRM2CYSLTR1MAPTL3MBTL1HTT | |
| Hydrochloric Acid SCHEMBL2949438 | 0.88 | MRGPRX4 (0.53) | GRM2CYSLTR1MAPTL3MBTL1HTT | |
| SCHEMBL12231479 | 0.84 | GRM2 (0.49) | GRM2CYSLTR1MAPTL3MBTL1HTT | |
| SCHEMBL2940440 | 0.82 | GRM2 (0.52) | GRM2CYSLTR1MAPTL3MBTL1HTT | |
| Hydrochloric Acid SCHEMBL2949437 | 0.81 | GRM2 (0.51) | GRM2CYSLTR1MAPTL3MBTL1HTT | |
| SCHEMBL12231469 | 0.80 | GRM2 (0.50) | GRM2CYSLTR1MAPTL3MBTL1HTT | |
| Hydrochloric Acid SCHEMBL27831476 | 0.79 | MRGPRX4 (0.56) | GRM2CYSLTR1MAPTL3MBTL1HTT | |
| SCHEMBL12231474 | 0.78 | GRM2 (0.50) | GRM2CYSLTR1MAPTL3MBTL1HTT | |
| SCHEMBL27831471 | 0.77 | GRM2 (0.47) | GRM2CYSLTR1MAPTL3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318375-B1 | IMIDAZOLE CARBOXAMIDES | LILLY CO ELI (US) | 2012-09-19 | — | — | EP | disclosed |
| US-7754742-B2 | Imidazole carboxamides | ELI LILLY AND COMPANY (US) | 2010-07-13 | — | — | US | disclosed |
| WO-2010009062-A1 | IMIDAZOLE CARBOXAMIDES | ELI LILLY AND COMPANY (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016373-A1 | IMIDAZOLE CARBOXAMIDES | ELI LILLY AND COMPANY | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016373-A1 | IMIDAZOLE CARBOXAMIDES | CYP3A4, CYP2C9, AADAC | GRM2 2836/4885CYSLTR1 2163/4885MAPT 1712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.